# Avastin (Bevacizumab) and RAD001 (Everolimus) in Advanced Low or Intermediate Grade Neuroendocrine Carcinoma

> **NCT00607113** · PHASE2 · COMPLETED · sponsor: **M.D. Anderson Cancer Center** · enrollment: 41 (actual)

## Conditions studied

- Neuroendocrine Carcinoma

## Interventions

- **DRUG:** Avastin
- **DRUG:** RAD001

## Key facts

- **NCT ID:** NCT00607113
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-01
- **Primary completion:** 2011-10
- **Final completion:** 2011-10
- **Target enrollment:** 41 (ACTUAL)
- **Last updated:** 2013-07-18

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00607113

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00607113, "Avastin (Bevacizumab) and RAD001 (Everolimus) in Advanced Low or Intermediate Grade Neuroendocrine Carcinoma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00607113. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*